A study to learn how Lu AG06466 and one of its break down products binds in the brain after single and repeated dosing
The study will be conducted in two Parts. Part A: cross over, fed/fasted determined by randomized sequence Part B: sequential group PET scans will be used to quantify MAGL occupancy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
capsules, orally
UZ Leuven campus Gasthuisberg
Leuven, Belgium
Central monoacylglycerol lipase (MAGL) occupancy
Time frame: From dosing to 8 hours post-dose
C(PET)
Average plasma concentration for Lu AG06466 and Lu AG06988 during PET imaging
Time frame: From zero to Day 10
AUC (0-24)
Area under the plasma concentration curve for Lu AG06466 and Lu AG06988 from zero to 24 hours
Time frame: From zero to 24 hours post-dose
Cmax
Maximum observed plasma concentration for Lu AG06466 and Lu AG06988
Time frame: From zero to 24 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.